WO2004024953A1 - Procede pour preparer des marqueurs d'adnc servant a identifier des genes exprimes et procede d'analyse d'expression genetique - Google Patents

Procede pour preparer des marqueurs d'adnc servant a identifier des genes exprimes et procede d'analyse d'expression genetique Download PDF

Info

Publication number
WO2004024953A1
WO2004024953A1 PCT/JP2003/009901 JP0309901W WO2004024953A1 WO 2004024953 A1 WO2004024953 A1 WO 2004024953A1 JP 0309901 W JP0309901 W JP 0309901W WO 2004024953 A1 WO2004024953 A1 WO 2004024953A1
Authority
WO
WIPO (PCT)
Prior art keywords
linker
cdna
restriction enzyme
type iis
iis restriction
Prior art date
Application number
PCT/JP2003/009901
Other languages
English (en)
Inventor
Mikio Yamamoto
Naoki Yamamoto
Kunitaka Hirose
Jun Sakai
Original Assignee
Kureha Chemical Industry Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kureha Chemical Industry Company, Limited filed Critical Kureha Chemical Industry Company, Limited
Priority to AU2003250546A priority Critical patent/AU2003250546A1/en
Priority to EP03795210A priority patent/EP1537242A1/fr
Publication of WO2004024953A1 publication Critical patent/WO2004024953A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C12Q1/6855—Ligating adaptors

Definitions

  • the present invention relates to a method for the preparation of cDNA tags for identifying expressed genes, a cDNA library prepared by the method and a method for the analysis of gene expression. More specifically, the invention relates to the method for the preparation of cDNA tags hybridizing to mRNAs as products of expressed genes, cDNAs corresponding to the mRNAs or given areas of the cDNA fragments, and the method for analysis of gene expression using the cDNAs.
  • the method for the analysis of gene expression includes a direct method using the cDNA tags without any processing and an indirect method using a concatemer of the cDNA tags.
  • Each species has the peculiar gene expression pattern based on the original genomic sequence.
  • each all or organ shows different gene expression patterns depending on a physiological stage such as degree of differentiation, multiplication and aging, or a pathological state such as canceration, infectious disease and immunologic disease. Accordingly, when such gene expression patterns are compared with each other, the differences provides valuable information which can be used in a variety of ., applications such as identification of appropriate treatment targets, identification of candidate genes for a gene therapy, tissue typing, legal gene confirmation, positioning of disease related genes and identification of indicator genes for diagnosis.
  • SAGE serial analysis of gene expression
  • the SAGE can analyze lots of transcripts by identifying a given region of the transcripts corresponding to the expressed genes.
  • the patterns of gene expression are determined by preparing tags referred to as "ditag" which are formed by ligating randomly two of short nucleotides corresponding to each cDNA in a sample, connecting the ditags like a chain to form concatemers, cloning and sequencing each concatemer to determine the pattern of gene expression.
  • the SAGE cannot provide a single cDNA tag for identifying expressed gene corresponding to each cDNA in a sample and the number of expressed genes to be identified at a time is limited to 1 ,000 or less, usually 400 or less because the concatemer can contain the limited number of the ditags.
  • the inventors have developed a method for the preparation of cDNA tags for identifying expressed genes and a method for the analysis of gene expression using the cDNA tags, which are described in PCT/JP02/02338.
  • An object of the present invention is to provide an improvement of the method of PCT/JP02/02338 in that, for example the restriction enzymes used therein can be selected from a broader aspect than those of the previous invention and the linkers used therein can be prepared more easily as well as provide the better method for the analysis of gene expression.
  • the present invention provides a method for the preparation of cDNA tags for identifying expressed genes, which enables to conduct the efficient analysis of peculiar gene expression pattern of each species, and of specific gene expression patterns depending on a physiological state, on a development step, or on a pathological states of cells or organs, and also provides a method for the gene expression using the cDNA tags.
  • the method of the present invention requests a less amount of cell samples for the analysis of gene expression and is more efficient and reliable than the conventional technologies.
  • the present invention provides a method for the preparation of cDNA tags for identifying expressed genes comprising: providing complementary deoxyribonucleic acids (cDNAs); cleaving the cDNAs with a type II restriction enzyme to prepare cDNA fragments; ligating the cDNA fragments to linker Xes which have a recognition site of a first type IIS restriction enzyme and which form a recognition site of a second type IIS restriction enzyme at the site linking with the cleavage end of the cDNA fragments formed by the type II restriction enzyme to prepare linker X-cDNA fragment complexs; cleaving the linker X-cDNA fragment complexs with the second type II restriction enzyme to prepare linker X-cDNA tag complexs; ligating linker Ys which have a recognition site of a third type IIS restriction enzyme to the cleavage end of the linker X-cDNA tag complexs formed by the second type IIS restriction enzyme to prepare linker X-cDNA tag-linker Y complexs; amplifying
  • the present invention also provides a method for the preparation of cDNA tags for identifying expressed genes comprising: providing complementary deoxyribonucleic acids (cDNAs); cleaving the cDNAs with a type II restriction enzyme to produce cDNA frangments; ligating the cDNA fragments to linker Xes which have recognition sites of first and second type IIS restriction enzymes to prepare linker X-cDNA fragment complexs; cleaving the linker X-cDNA fragment complexs with the second type IIS restriction enzyme to prepare linker X-cDNA tag complexs; ligating linker Ys which have a recognition site of the first type IIS restriction enzyme to the cleavage end of the linker X-cDNA tag complexs formed by the second type IIS restriction enzyme to prepare linker X-cDNA tag-linker Y complexs; amplifying the linker X-cDNA tag-linker Y complexs; and cleaving the amplified products thus obtained with the first IIS restriction enzyme to prepare the
  • the present invention further provides a method for the preparation of cDNA tags for identifying expressed genes comprising: providing complementary deoxyribonucleic acids; cleaving the cDNAs with a type II restriction enzyme to produce cDNA fragments; ligating the cDNA fragments to linker Xes which have recognition sites of first and second type IIS restriction enzymes to prepare linker X- cDNA fragment complexs; cleaving the linker X-cDNA fragment complexs with the second type IIS restriction enzyme to prepare linker X-cDNA tag complexs; ligating linker Ys which have a recognition site of a third type IIS restriction enzyme to the cleavage end of the linker X-cDNA tag complexs formed by the second type IIS restriction enzyme to prepare linker X-cDNA tag-linker Y complexs; amplifying the linker X-cDNA tag-linker Y complexs; and cleaving the amplified products thus obtained with the first and third type IIS restriction enzymes simultaneously or in
  • the present invention further provides a method for the analysis of gene expression wherein the library of cDNA tags prepared by the method described above is contacted with a detector on which nucleic acids to be detected are immobilized.
  • the present invention further provides a method for the analysis of gene expression wherein a library of nucleic acids to be detected is connected with the detector on which the cDNA tags prepared by the method of the present invention are immobilized. DNA chips may be used as the detector therefore.
  • the present invention further provides a method for the analysis of gene expression comprising the steps of concatenating the cDNA tags for identifying expressed genes prepared by the method described above to form concatemers and sequencing the concatemers.
  • the method for the analysis includes a method for the qualitative analysis of gene expression wherein the concatemers are sequenced and then each of the cDNA tags are sequenced on the basis of the sequences of the concatemers, and a method for the quantitative analysis of gene expression wherein each of the cDNA tags are sequenced and measured in frequency of occurrences on the basis of the sequences of the concatemers.
  • the present invention further provides a kit for the preparation of cDNA tags for identifying expressed genes wherein the kit comprises a type II restriction enzyme, a first type IIS restriction enzyme, a second type IIS restriction enzyme, a third type IIS restriction enzyme, linker Xes which have a recognition site of the first type IIS restriction enzyme and which form a recognition site of the second type IIS restriction enzyme at the site linking with the cleavage end of the cDNA fragments formed by the type II restriction enzyme to prepare linker X-cDNA fragment complexs and linker Ys which have a recognition site of the third type IIS restriction enzyme.
  • the kit comprises a type II restriction enzyme, a first type IIS restriction enzyme, a second type IIS restriction enzyme, a third type IIS restriction enzyme, linker Xes which have a recognition site of the first type IIS restriction enzyme and which form a recognition site of the second type IIS restriction enzyme at the site linking with the cleavage end of the cDNA fragments formed by the type II restriction enzyme to prepare
  • the present invention further provides a kit for the preparation of cDNA tags for identifying expressed genes wherein the kit comprises a type II restriction enzyme, a first type IIS restriction enzyme, a second type IIS restriction enzyme, linker Xes which have recognition sites of the first and the second type IIS restriction enzymes and linker Ys which have a recognition site of the first type IIS restriction enzyme.
  • the present invention further provides a kit for the preparation of cDNA tags for identifying expressed genes wherein the kit comprises a type II restriction enzyme, a first type IIS restriction enzyme a second type IIS restriction enzyme, a third type IIS restriction enzyme, linker Xes which have recognition sites of the first and second type IIS restriction enzymes and linker Ys which have a recognition site of the third type IIS restriction enzyme.
  • cDNA tag for identifying expressed gene may be abbreviated as cDNA tag for IEG, if necessary.
  • a short nucleotide sequence isolated from a defined region within a gene transcript has sufficient information to identify the transcript. For example, a sequence of 9 bp may have combinations of the ninth power of four, 262, 144 and therefore the sequence can identify the same number of the transcripts. Whereas, estimates suggest that the human genome encodes about 80,000 to 200,000 transcripts (Fields, et aL, Nature Genetics, 1 :345 1994). Principally, if the tags of 9bp are obtained, all of the transcripts of the human genome can be identified.
  • the size of the tag may be shorter, where a subject of the analysis is a lower eukaryote or prokaryote, because the number of transcripts encoded by the genome is lower. For example, a tag of 6 to 7 bp may be sufficient for distinguishing the transcripts in yeast.
  • the present invention can provide single cDNA tags of the same length for identifying expressed genes with a variety of lengths and therefore is useful in the analysis of gene expression patterns. Second, the present invention can provide extremely reduced bias caused by amplification and/or cloning because the invention allows analyzing a gene expression by once amplification of a single short cDNA tag interposed between upstream and downstream linkers.
  • a library of the cDNA tags prepared according to the present invention can be used to qualitatively or quantitatively detect the cDNAs corresponding to the cDNA tags for the analysis of gene expression patterns.
  • concatemers with or without spacer sequences of the cDNA tags prepared by the method of the present invention allows serial and efficient analysis of gene expression.
  • the concatemers may be cloned by vector and the like.
  • the cDNA tags have independent sequences individually, it is easy to sequence each of the concatemers and to singly isolate the cDNA tags from the concatemers.
  • a tag of short nucleotide sequence has sufficient information to identify the transcript.
  • the SAGE uses a complexized tag referred to as "ditag”.
  • the SAGE is different from the present invention in that the SAGE does not prepare and use a single cDNA tag for identifying expressed gene of the present invention, a library thereof and a concatemer of the single cDNA tags.
  • FIG. 1 Each figure is a process drawing, which shows the process of embodiment of the method for the preparation of cDNA tags for identifying expressed genes according to the present invention.
  • the letter "N" in the figures means any one of A, T, G, or C.
  • Figure 1 shows steps (1 ) to (6) of the method for the preparation of cDNA tags according to the invention using linker X having a recognition site of third type IIS restriction enzyme.
  • Figure 2 shows steps (7) to (10) of the method for the preparation of cDNA tags according, to the invention using linker Y having a recognition site of a third type IIS restriction enzyme.
  • Figure 3 shows steps (1) to (6) of the method for the preparation of cDNA tags according to the invention using linker X having recognition sites of first and second type IIS restriction enzymes.
  • Figure 4 shows steps (7) to (10) of the method for the preparation of the cDNA tags according to the invention using linker X having recognition sites of first and second type IIS restriction enzymes.
  • Figure 5 shows steps (1) to (6) of the method for the preparation of the cDNA tags according to the invention using linker X having recognition sites of first and second type IIS restriction enzymes and linker Y having a recognition site of third type IIS restriction enzyme.
  • Figure 6 shows steps (7) to (10) of the method for the preparation of the cDNA tags according to the invention using linker X having recognition sites of first and second type IIS restriction enzymes and linker Y having a recognition site of third type IIS restriction enzyme.
  • cDNA tag or cDNA tag for IEG
  • the method for the preparation of cDNA tags according to the present invention has three modes.
  • the present invention provides the following modes: a method comprising the step of ligating linker Ys which have a recognition site of a third type IIS restriction enzyme to the cleavage end of the linker X-cDNA tag complexs formed by a second type IIS restriction enzyme (mode 1); a method comprising the step of ligating linker Xes which have recognition sites of first and second type IIS restriction enzymes to given cDNA fragments (mode 2); and a method comprising a combination of the both steps using said linker Xes and linker Ys (mode 3).
  • the method comprising the steps of:
  • cDNAs complementary deoxyribonucleic acids
  • mode 1 of the invention can use many kinds of restriction enzymes.
  • linker X as used in mode 1 means a linker which has a recognition site of a first type IIS restriction enzyme and which forms a recognition site of a second type IIS restriction enzyme at the site linking with the cleavage end of the cDNA fragments formed by the type II restriction enzyme.
  • linker Y means a linker having a recognition site of a third type IIS restriction enzyme.
  • linker X linker Y
  • primer X primer Y
  • Linker X 5'-- NNNNNNNGAGGAGNNNNNGGG - -3' (SEQ ID NO: 1)
  • Primer Y 3'— ⁇ TGNNNNNNNNNAGGCGGNNNNNNN - -5' (SEQ ID NO: 6)
  • cDNAs complementary deoxyribonucleic acids
  • linker Xes which have recognition sites of first type IIS restriction enzyme BseRI and second type IIS restriction enzyme Bsgl to prepare linker X-cDNA fragment complexs
  • mode 2 of the invention can use many kinds of restriction enzymes.
  • linker X as used in the description of mode 2 means a linker which has a recognition site of first type IIS restriction enzyme and a recognition site of second type IIS restriction enzyme Bsgl.
  • linker Y means a linker having the same recognition site of the first type IIS restriction enzyme used in the linker X. Specific sequences of linker X, linker Y, primer X and primer Y used in mode 2 are shown below.
  • Linker X 5'--" NNNNNNNGAGGAGNGTGCAG --- -3' (SEQ ID NO: 7)
  • cDNAs complementary deoxyribonucleic acids
  • linker Xes which have recognition sites of first type IIS restriction enzyme BseRI and second type IIS restriction enzyme Bsgl to prepare linker X-cDNA fragment complexs
  • linker X-cDNA fragment complexs (4) cleaving the linker X-cDNA fragment complexs with second type IIS restriction enzyme Bsgl to prepare linker X-cDNA tag complexs;
  • linker X as used in the description of mode 3 means a linker which has a recognition site of first type IIS restriction enzyme and a recognition site of second type IIS restriction enzyme.
  • linker Y means a linker having a recognition site of third type IIS restriction enzyme.
  • cDNAs are prepared as a sample. Normally, mRNAs are prepared from the cells to be examined and then the cDNAs are prepared by conventional procedure with a reverse transcriptase.
  • the cDNAs may be sequences corresponding to the full-length mRNAs, fragments of the mRNAs or a combination thereof.
  • the cells to be examined are not limited and may be all the cells including animal cells, plant cells, and microbial cells, where the cells produce mRNAs having a poly A tail at the 3' end. Virus-infected animal cells, plant cells or microbial cells may also be used as the cells to be examined in the invention.
  • a method of the present invention can analyze a gene expression when one microgram (ug) of mRNAs from the sample is available. Since 1 ug of mRNAs can be normally obtained from 1 mg of the cells to be examined, the present invention is particularly useful in handling precious human tissue samples obtained by needle biopsy. Isolation of mRNAs from the cells to be examined may be performed by conventional procedure. For example, the mRNAs are obtained by treating the cells with a guanidine reagent or a phenol reagent to isolate total RNAs and then performing an affinity-column method or a batch method using an oligo dT- cellulose or Sepharose 2B as a carrier.
  • the first chain cDNAs (single-stranded cDNAs) are synthesized with the resultant mRNAs as a template using oligo dT primers and a reverse transcriptase and then the second chain cDNAs (double-staranded cDNAs) are synthesized with the first chain cDNAs as a template.
  • the oligo dT primers used herein include an oligo dT primer immobilized on a solid phase and an oligo dT primer labeled with a coenzyme marker.
  • the oligo dT primer immobilized on a solid phase is preferable.
  • the oligo dT primers immobilized on a solid phase may be oligo dT primers immobilized on latex beads or oligo dT primers immobilized on magnet beads, preferably the oligo dT primers immobilized on magnet beads.
  • step (2) the cDNAs in the sample are cleaved with a type II restriction enzyme to prepare the cDNA fragments.
  • the cDNAs in the sample may be double- stranded cDNAs combined with the oligo dT primers immobilized on a solid phase.
  • type II restriction enzyme as used herein means a restriction enzyme which recognizes a given recognition site and then cleaves the DNA at a specific position inside of or adjacent to the recognition site.
  • the type II restriction enzyme used in the present invention is a restriction enzyme having at least one recognition site of the mRNA to be analyzed, for example, preferably a type II restriction enzyme having a recognition site consisting of 4, 5 or 6 bases.
  • a type II restriction enzyme having a recognition site of four bases is preferable to the invention because the enzyme theoretically has a recognition site per the fourth power of four, 256 bases.
  • the type II restriction enzymes used in the invention include Afal, Alul, Cful, CviRI, Dpnl, EsaBC3I, HpyBI, HpyCH4V, HpyF44III, Mltl, PlaAII, Rsal, Bfal, Csp6I, CviAII, CviQI, CviRII, Fgol, HpyCH4IV, Mael, Maell, MthZI, Rmal, PpaAII, Taql, Tsp32I, Tsp32II, TthHB ⁇ l, Xspl, BspKT6I, BstKTI, HpyCH4I, AspMDI, Bce243I,
  • the type II restriction enzymes have a recognition site consisting of all the four bases, A, T, C and G or other recognition site consisting of C and G or A and T.
  • the type II restriction enzyme having a recognition site consisting of all the four bases, A, T, C and G include Afal, Alul, Cful, CviRI, Dpnl, EsaBC3I, HpyBI, HpyCH4N HpyF44III, Mltl, PlaAII, Rsal, Bfal, Csp6I, CviAII, CviQI, CviRII, Fgol,
  • the type II restriction enzymes having a recognition site consisting of bases C and G include AccII, BanAI, BceBI, BecAII, Bepl, Biml 9II, Bme361 I, Bpu95I, BseQI, Bshl, Bshl236I, BshFI, Bsp50I, Bspl23I, Bsp211I, BspBRI, BspKI, BspRI, BstF ⁇ I, BstUI, Bsul 532I, BsuRI, Btgl, Btkl, Cltl, Csp68KVI, CspKVI, Dsall, EsaBC4I, Falll, FauBII, FnuDI, FnuDII, Haelll, MchAII, MfoAI, MfoAI, Mvnl, ⁇ goPII, ⁇ spLKI, Pall, Pde l 33I, PflKI, Plal,
  • the type II restriction enzymes having a recognition site consisting of bases A and T include Msel, Trull, Tru9I, Sse9I, Tasl, Tsp509I and TspEI.
  • the restriction enzyme is preferably selected in light of the features of these recognition sites.
  • step (3) linker Xes having recognition sites of the first and second type IIS restriction enzymes are ligated to the cDNA fragment to prepare the linker X- cDNA fragment complexs.
  • cDNA fragments having an oligo dT primer sequence are isolated from the group of the cDNA fragments prepared in step (2). The isolation may be performed by using a label of oligo dT primer. For example, where oligo dT primers immobilized on latex beads are used for the preparation of said cDNAs, the cDNAs may be treated with type II restriction enzyme, centrifuged to precipitate in the form of cDNA fragments having the oligo dT primer sequences immobilized on the beads and then isolated.
  • the cDNA fragments thus obtained are those having a poly A tail and a cleavage-end of said type II restriction enzyme which first appears in the 5' upstream direction from the poly A tail.
  • the cDNA fragments are ligated to linker Xes using DNA ligase such as T4 DNA ligase.
  • a recognition site of the first type IIS restriction enzyme in linker Xes may be located so that the first type IIS restriction enzyme cleaves the cDNA tag leaving no spacer sequence or a desired spacer sequence at an appropriate position.
  • linker X may be a double-stranded DNA fragment having the following structure.
  • the sequence "5'-GAGGAG-3' "in the linker X is the recognition site of first type IIS restriction enzyme BseRI.
  • the sequence "5'-GTGCAG-3' " at 3 ' end of the linker X is the recognition site of second type IIS restriction enzyme Bsgl.
  • the letter “N” or “n” in base sequence as used herein means any one of bases A, T, C and G.
  • first type IIS restriction enzyme principally means a type IIS restriction enzyme which can recognize the recognition site on linker X and which forms a desired cDNA tag for IEG, or a type I or III restriction enzyme which has the same function as that of the type IIS restriction enzyme.
  • the first type IIS restriction enzymes used in the invention include Mmel, Acul, Bce83I, Bpml, BpuEI, Bsgl, BspKT5I, Eco57I, Eco57MI, Gsul, BsmFI, BspLUl lIH, BstOZ616I, Stsl, BceAI, BstPZ418I, Fokl, Bcefl, AlwXI, Bbvl, Bsp423I, BseKI, BseXI, Bsp423I, Bstl2I, Bst71I, BstVlI, RleAI, Acelll, Bbr7I, Ecil, TspDTI, TspGWI, Tthl l l ll, Hgal, BseMII, BseRI, BspST5I, Lwel, Phal, SfaNI, Aarl, Acc36I, BfuAI, BspMI, Bvel
  • the first type IIS restriction enzymes having a distance of ten or more bases from the recognition site to the farthest end include Mmel, Acul, Bce83I, Bpml, BpuEI, Bsgl, BspKT5I, Eco57I, Eco57MI, Gsul, BsmFI, BspLUl lIH, BstOZ616I, Stsl, BceAI, BstPZ418I, Fokl, Bcefl, AlwXI, Bbvl, Bsp423I, BseKI,
  • the first type IIS restriction enzymes having the distance of 16 or more bases include Mmel, Acul, Bce83I, Bpml, BpuEI, Bsgl, Bs ⁇ KT5I, Eco57I, Eco57MI and Gsul.
  • second type IIS restriction enzyme means a type IIS restriction enzyme which can recognize a recognition site on linker X or a recognition site formed in a linking site of linker X-cDNA fragment complex and which cleaves cDNA fragments at an appropriate point, or a type I or III restriction enzyme which has the same function as that of the type IIS restriction enzyme.
  • the linker X-cDNA tag complex is prepared by cleaving with the second type IIS restriction enzyme.
  • the second type IIS restriction enzymes include Mmel, Acul, Bce83I, Bpml, BpuEI, Bsgl, BspKT5I, Eco57I, Eco57MI, Gsul, BsmFI, BspLUl lIH, BstOZ616I, Stsl, BceAI, BstPZ418I, Fokl, Bcefl, AlwXI, Bbvl, BseKI, BseXI, Bsp423I, Bstl 2I, Bst71 I, BstVlI, RleAI, Acelll, Bbr7I, Ecil, TspDTI, TspGWI, Tthl l lll, Hgal, BseMII, BseRI, BspST5I, Lwel, Phal, SfaNI, Aarl, Acc36I, BfuAI, BspMI, Bvel, Sthl32I, SspD5
  • the second type IIS restriction enzymes having a distance of ten or more bases from the recognition site to the farthest end include Mmel, Acul, Bce83I, Bpml, BpuEI, Bsgl, BspKT5I, Eco57I, Eco57MI, Gsul, BsmFI, BspLUl lIH, BstOZ616I, Stsl, BceAI, BstPZ418I, Fokl, Bcefl, AlwXI, Bbvl, BseKI,
  • the second type IIS restriction enzymes having the distance of 16 or more bases include Mmel, Acul, Bce83I, Bpml, BpuEI, Bsgl, BspKT5I, Eco57I, Eco57MI and Gsul. Since there is no need to define a sequence of cleavage site formed by the first type IIS restriction enzyme, a combination of the first and second type IIS restriction enzymes is not limited.
  • linker X should have the end which may combine with a cDNA fragment formed with the type II restriction enzyme to form the linker X-cDNA fragment complex or the end which can be processed so that it may form the complex
  • a combination of type II restriction enzyme and the first or the second type IIS restriction enzyme is not limited.
  • linker Y should have a random sequence having the bases, the number of which is the difference between them.
  • the type IIS restriction enzymes falling under the type above include Mmel, Acul, Bce83I, Bpml, BpuEI, Bsgl, BspKT5I, Eco57I, Eco57MI, Gsul, RleAI, Ecil, TspDTI, TspGWI, Tthl l lll, BseMII, BseRI, AsuHPI, Hphl, MboII, Ncul, Mnll, BciVI, Bful and HpyAN
  • step (4) the linker X-cD ⁇ A fragment complexs are cleaved with the second type IIS restriction enzyme to prepare the linker X-cD ⁇ A tag complexs.
  • the enzyme recognizes the double-stranded D ⁇ A containing the recognition site "5'- GTGCAG-3' " on the linker X-cD ⁇ A fragment complex and the complementary sequence and then cleaves the site "5'-GTGCAG-3'(16/14)".
  • Bsgl cuts a phosphodiester bond between the bases located at 16 bp and 17 bp 3 '- downstream from the base "G" of the 3 '-end of recognition site "5'-GTGCAG-3' " and a phosphodiester bond between the bases located at 14 bp and 15 bp 5 ' upstream from the base "C” of 5 '-end of complementary chain "3'-CACGTC-5' " of the recognition site "5'-GTGCAG-3' ".
  • the resultant DNA fragment has the cleavage end having the following structure.
  • step (5) the linker X-cDNA tag complexs obtained in step (4) by cleaving the linker X-cDNA fragment complexs with the second type IIS restriction enzyme are refined, if necessary.
  • This refinement may be done by, as described in step (3), removing the rest of the cDNA fragments cut away from the cDNA tags using oligo dT primers.
  • the solution of the cDNAs treated with the restriction enzyme may be centrifuged to precipitate and then remove the cDNA fragments having labeled oligo dT primers.
  • the supernatant from the centrifugation includes the linker X-cDNA tag complexs.
  • step (6) the cleavage end of the linker X-cDNA tag complexs formed by the second type IIS restriction enzyme is processed to ligate linker Y having recognition site of the third type IIS restriction enzyme.
  • linker Ys are ligated to the cleavage end of the linker X-cDNA tag complexs to prepare linker X-cDNA tag-linker Y complexs.
  • linker Y as used herein means a linker having recognition sites of the first or third type IIS restriction enzymes. The recognition sites are preferably located so that the type IIS restriction enzyme may cleave the cDNA tags out without leaving spacer sequences or with leaving spacer sequences at an appropriate point.
  • the linker Y to be ligated may be the DNA fragment having the following structures. In this example, the linker Y is designed so that two residues A and C may leave as a spacer sequence.
  • the linker X-cDNA tag-linker Y complexs prepared in step (7) may have, for example the following sequences.
  • third type IIS restriction enzyme means a type IIS restriction enzyme, which is used instead of the first type IIS restriction enzyme, having a recognition site on linker Y and being capable of forming a desired cDNA tag, or a type I or III restriction enzyme having the same function as that of the type IIS restriction enzyme.
  • the third type IIS restriction enzymes include, for example Mmel, Acul, Bce83I, Bpml, BpuEI, Bsgl, BspKT5I, Eco57I, Eco57MI, Gsul, BsmFI, BspLUl lIH, BstOZ616I, Stsl, BceAI, BstPZ418I, Fokl, Bcefl, AlwXI, Bbvl, Bsp423I, BseKI,
  • the third type IIS restriction enzymes having a distance of ten or more bases from the recognition site to the farthest end include Mmel, Acul, Bce83I, Bpml, BpuEI, Bsgl, BspKT5I, Eco57I, Eco57MI, Gsul, BsmFI, BspLUl lIH, BstOZ616I, Stsl, BceAI, BstPZ418I, Fokl, Bcefl, AlwXI, Bbvl, Bsp423I, BseKI, BseXI, Bsp423I, Bstl2I, Bst71 I, BstVlI, RleAI, Acelll, Bbr7I, Ecil, TspDTI, TspGWI, Tthl l lll, Hgal, BseMII and BseRI.
  • the third type IIS restriction enzymes having the distance of 16 or more bases include Mmel, Acul
  • a combination of the first and third type IIS restriction enzymes is not limited, even if the both of the enzymes are the same. Where the reaction system is the same or similar to each other among the combinations of the first and the third type IIS restriction enzymes, the both of the enzymes may be reacted simultaneously or the step of removing the enzyme or the salt may be omitted in step (9) described hereinafter.
  • step (8) provides with the complex having the structure "5'-[linker X]- [cDNA tag (cDNA tag for IEG)]-[linker Y]-3 '".
  • step (8) the linker X-cDNA tag-linker Y complexs are amplified.
  • the complexs obtained by step (7) have sequences in linkers X and Y to which primers X and Y may hybridize respectively and may be easily amplified by polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • the standard polymerase chain reaction method may be used for the present invention, for example the method described in USP No. 4,683, 195.
  • the complex may be amplified by cloning the one that is ligated into a vector adaptable to a prokaryote or by another method for the amplification known to those skilled in the art.
  • the amplification efficiency varies depending on the length of each template DNA. Generally, as the strands are long, the efficiency of the amplification becomes lower and vice versa. As a result, an occurrence ratio of each amplified fragment in the amplified products thus obtained does not reflect the abundance ratio of correcponding DNA fragment in the mixture of template DNA. In contrast, since the template DNA used in present invention have the same length and is short, the occurrence ratio of each amplified DNA fragment in the resultant amplified products should reflect the abundance ratio of corresponding DNA fragment in the mixture of template DNAs.
  • the PCR method may be performed under standard conditions of time and temperature in the present invention. Since the linker X-cDNA tag-linker Y complex used in the invention provides a high efficiency of amplification due to its short and equal in length, the number of annealing/sequence extension cycles may be reduced. In addition, since an efficiency of the PCR method may vary due to a change in the sequence of linker, appropriate linkers used in the procedure may give a desired efficiency of annealing/sequence extension cycle.
  • primer X as used herein means a naturally-occurring or synthesized oligo nucleotide which is complementary to a nucleic acid strand of linker X and may work as an initiation point under conditions that the PCR starts.
  • the primer X should have a length enough to hybridize at the site where a recognition site of the first type IIS restriction enzyme on linker X is retained and to initiate the amplification in the presence of an agent for polymerization. A required length of primer X will be determined due to lots of factors such as temperature, pH and ligase used in the PCR.
  • primer Y means a naturally- occurring or synthesized oligo nucleotide which is complementary to a nucleic acid strand of linker Y and may work as an initiation point under conditions that the PCR starts.
  • the primer Y should have a length enough to hybridize at the site where recognition sites of the first and third type IIS restriction enzymes on linker Y are retained and to initiate the amplification in the presence of an agent for polymerization.
  • step (9) of Mode 3 the resultant amplified-products are cleaved with the first and third type IIS restriction enzymes simultaneously or in turn with inserting the additional step of removing the enzyme and salt between the cleaving steps using the first or third enzymes, if necessary, to prodece the cDNA tags.
  • the first and third type IIS restriction enzymes may be selected independently. Where the cleavage is performed in turn, either of the enzymes may be used optionally in order of use.
  • BseRI is used as a first type IIS restriction enzyme
  • the enzyme recognizes the double-stranded DNA consisting of sequence "5'-GAGGAG-3"' on the linker X and its complementary strand and then cleaves the site "5'-GAGGAG- 3'(10/8)".
  • BseRI cuts a phosphodiester bond between the bases located at 10 bp and 1 1 bp 3 '- downstream from the base "G" of the 3 '-end of recognition site "5'- GAGGAG-3"' and a phosphodiester bond between the bases located at 8 bp and 9 bp 5'-upstream from the base "C” of 5'-end of complementary chain "3'-CTCCTC-5"' of the recognition site "5'-GAGGAG-3' ".
  • the resultant DNA fragment of linker X with the cleavage end having the following structure is prepared.
  • Ecil is used as a third type IIS restriction enzyme
  • the enzyme recognizes the double-stranded DNA consisting of sequence "5'-GGCGGA- 3"" on the linker Y and its complimentary strand and then cleaves the site "5'- GGCGGA-3'(l l/9)".
  • Ecil cuts a phosphodiester bond between the bases located at 11 bp and 12 bp 3 '- downstream from the base "A" of the 3 '-end of recognition site "5'-GGCGGA-3”' and a phosphodiester bond between the bases located at 9 bp and 10 bp 5 '-upstream from the base "T” of 5'-end of complementary chain "5'-TCCGCC-3"' of the recognition site "5'-GGCGGA-3”'.
  • the resultant DNA fragment of linker Y with the cleavage end having the following structure is prepared.
  • the cDNA tag is cut out from the DNA fragments including linkers X and Y.
  • the cDNA tag consisting of sequences Nos.25 and 26, comprising a nucleotide chain of thirteen bases immediately adjacent to Csp6I cleavage end (5 '-AC-3 ') of the cDNA fragment derived from the cDNA to be examined, by using Cps6I as a type II restriction enzyme in step (2), linker X comprising a nucleotide chain consisting of base sequences of SEQ ID NOs: 13 and 14 in step (3), Bsgl as a second type IIS restriction enzyme in step (4), linker Y comprising a nucleotide chain consisting of base sequences of SEQ ID NOs: 17 and 18 in step (7), and BseRI as a first type IIS restriction enzyme and Ecil as a third type IIS restriction enzyme.
  • a library of the cDNA tags is obtained in step (9).
  • the cDNAs corresponding to the cDNA tags for identifying expressed genes can be qualitatively or quantitatively detected to analyze a pattern of gene expression by utilizing the resultant library of the cDNA tags.
  • a selection of target genes can be conducted by providing a detector having spots of a library of cDNA tags corresponding to cDNAs to be detected, contacting each of a sample obtained from a subject and a standard sample, which are labeled with different markers respectively, with the detector and comparing relative signal strength of the different markers.
  • a wide range of known markers such as fluorescent marker and radio isotopic marker may be used in this step.
  • cDNA tags in a library of the cDNA tags can be detected to analyze a pattern of the gene expression by contacting the library with a detector to which the cDNAs to be detected are immobilized.
  • the detectors used for the present invention includes a microarray device such as DNA chip and a macroarray device such as dot hybridization.
  • Substrates used for the detector include Nylon membrane, nitrocellulose filter, glass plate and silicon chip-
  • the detector may be, for example a device for detecting target nucleic acids in which the resultant cDNA tags are immobilized on a substrate and then DNA, RNA and/or their fragments to be detected are hybridized thereon.
  • Samples are preferably labeled in a manner such that mRNAs or cDNAs can be detected.
  • markers in this step include radioisotope, fluorescent compound, bioluminescence compound, chemiluminescence compound, metal chelator or enzyme.
  • labeled cDNAs to be detected are melted into single strands, if necessary, gradually diluted and then contacted with a solid substrate holding the cDNA tags corresponding to genes to be detected in each grid of silicone chip.
  • a length of cDNA tag may be adjusted by selecting an appropriate second type IIS restriction enzyme. Although a desired length of cDNA tag may vary depending on a kind of species to be analyzed, the length of the DNA tag generally ranges from 6 to 25 bp, preferably from 10 to 25 bp and more preferably 10 to 16 bp.
  • the cDNA tag may be isolated, if necessary. The isolation may be conducted by conventional methods used by those skilled in the art such as polyacrylamide gel electrophoresis (PAGE).
  • expressed genes may be determined by ligating the cDNA tags to form a concatemer and then sequencing the concatemer. For example, since the cDNA tags obtained in step (9) have 3 '- and 5 '-cohesive ends which are complementary to each other, they can be ligated each other with T4 ligase.
  • the resultant concatemer of cDNA tags may be analyzed by methods, known to those skilled in the art, for example, cloning into a vector or sequencing with a sequencer.
  • concatemers generally consist of 3 to 200 of cDNA tags, preferably from 3 to 80 of cDNA tags and more preferably from 16 to 40 of cDNA tags.
  • the resultant concatemer may or may not have a spacer sequence between cDNAs tags depending on methods for the preparation of cDNA tags.
  • the concatemers of the present invention may be cloned by standard methods comprising the steps of integrating the tags into plasmids or phages and amplifying.
  • the term "recombinant vector” as used herein refers to a plasmid, virus or other vehicle prepared by inserting or cloning the concatemer of cDNA tags into it.
  • Such a vector includes an origin of replication, a promoter and a specific gene which allows a phenotypic selection of transformed cell.
  • many kinds of known cloning vectors suitable for sequencing may be used. Examples of such vectors include, but are not limited to, pUC 18, altered vectors of pUC 18 such as pUC118, pUC 19, altered vectors of pUC19 such as pUC119, M13 m pl 8RFI,
  • the recombinant vectors are transfected into an appropriate host cell.
  • host cell as used herein means a cell in which a vector may be amplified and a DNA of the vector may be expressed, or progenies thereof. Since a mutation may occur during their replication, all of the progenies are not always the same as their parent cell.
  • the present invention may utilize known and stable methods for transferring an exogenous gene by which the gene is continuously retained.
  • prokaryotic cells such as Escherichia coli
  • the cells are collected after the exponential growth phase and treated by know methods such as RbCl method and CaCl 2 method to prepare competent cells having an ability to uptake DNA.
  • the cells may be transformed by electroporation or conventional methods.
  • 20 or more cDNA tags preferably 20 to 100 cDNA tags and more preferably 20 to 30 cDNA tags can be sequenced in an operation by cloning a concatemer of the cDNA tags into a vector and sequencing the concatemer.
  • PBMC Peripheral blood mononuclear cells
  • the mRNA was isolated from the total RNA by adsorbing with Oligotex- MAG mRNA refinement kit (Takara Shuzo Co., LTD) and then double-stranded cDNAs were prepared from the mRNA by using cDNA synthesis kit (Takara Shuzo Co., LTD).
  • the resultant double-stranded cDNAs were cleaved by treating with restriction enzyme Csp6I (MBI Fermentas Inc.) at 37 degrees Celsius for two hours.
  • Linker X having the following structure was directly ligated to the cohesive end formed by cleaving with Csp6I.
  • the linker X-cDNA fragments were cleaved with Bsgl (New England Biolabs) at 37 degrees Celsius for two hours utilizing the recognition site of restriction enzyme Bsgl "5'-GTGCAG-3' " in the linker X.
  • the cleaved fragments having no beads, that is, the supernatant was collected. Since the cleavage site of the enzyme was at positon 5'-GTGCAG-3'(16/14), the collected fragments includes 13 base pairs derived from the cDNA following the linker X (except for common three residues "TAC" from Csp6I cleavage site).
  • linker X-AC- 13 bp derived from cDNA (cDNA tag)-AC-linker Y that is, a group of DNAs of whole length 52 bp including 13 bp derived from cDNAs interposed between known linkers.
  • This double-stranded fragment consists of the base sequence indicated below and its complementary chain.
  • the library of complexs consisting of small cDNA fragments were amplified by PCR method using Taq DNA polymerase, primer X comprising base sequence "5'- ACCGAGGAGTGTGCAGTA-3"' (SEQ ID NO:32) which hybridize the linker X region and primer Y comprising base sequence "5'-CCAGGCGGAGTCGCAGTGGT-3' " (SEQ ID NO:33) which hybridize the linker Y region.
  • the PCR method was performed by melting at 96 degrees Celsius for 30 seconds, annealing at 50 degrees Celsius for one minute and extending at 72 degrees Celsius for one minutes for 20 cycles and then finally extending at 72 degrees Celsius for two minites.
  • the treated products were electrophoresed through 12% polyacrylamide gel and isolated from the linker fragments to collect the small fragment DNAs.
  • the above concatemer was cloned into plasmid pUC l l ⁇ and sequenced the base sequence using DNA sequencer (ABI377).
  • DNA sequencer DNA sequencer
  • the genes specifically expressed in PBMC or the ones stimulated with LPS were analyzed. It is considered that about 10,000 of tag sequences need to be sequenced in order to approximately identify kinds and estimate appearance ratio of each mRNAs expressed in a cell. Since about 20 cDNA tags could be sequenced in one sequencing operation according to the invention, the kinds of mRNAs and the ratio can be estimated by determining base sequences of about 500 samples.
  • Tables 1 and 2 show the same genes identified by this method. A homology screening for base sequences of these cDNA tags was carried out by using known database. Table 1 shows the genes which were enhanced by LPS stimulation. Table 2 shows the genes which were suppressed by LPS stimulation.
  • Numbers designated as mf ID before base sequences in tables 1 and 2 are decimal numbers for computer processing which refer to sequences of 13 bases. Namely, the mf ID is a decimal number generated by substituting 0 for a, 1 for c, 2 for g and 3 for t to make a quaternary digit, converting the number to a decimal number and adding one.
  • Base sequences can be processed as a number regardless of their length. For example, when base sequences consisting of 13 bases are processed, the sequences can be identified by using the numbers in a manner indicated below.
  • any sequences consisting of 13 bases may be designated one ID number of eight digits. These figures are referred to as mini fragment ID (mf ID).
  • the library of the cDNA tags prepared in example 1 is detected with the detector described below to analyze the gene expression.
  • a DNA chip is produced by synthesizing oligo DNAs comprising sequences corresponding to mf base seqences designated as mf IDs 65462282, 55149444, 17350558, 58058765, 27500370 and 49078651 of the genes listed in Table 1 whose expression was activated by LPS stimulation, and spotting on a slide glass with the oligo DNAs using a conventional method.
  • mRNAs derived from the peripheral blood mononuclear cells (PBMC) obtained by LPS stimulation in example 1 which are used as a template were labeled with a fluorescent marker, fluorescent compound Cy3-dUTP (* 1) (Amersham Pharmacia), and other mRNAs derived from PBMC not stimulated with LPS which were used as a template were labeled with a fluorescent marker, fluorescent compound Cy5-dUTP (*5) (Amersham Pharmacia).
  • PBMC peripheral blood mononuclear cells
  • the probe solutions are mixed together to make 6 X SET [0.9M NaCl, 10 ⁇ g/ml Yeast tRNA, 0.1 %SDS, 120mM Tris-HCl(pH7.8)] solution and then keep in contact with said oligo DNA chip at 45 degrees Celsius overnight to perform hybridization.
  • the fuluorescent markers on the chip are scanned with a scanner to obtain the fluorescence intensity data and then the data is analyzed.
  • the scatter plot of signal intensity of Cy3 and Cy5 at each of the spots demonstrates that the fluorescent light radiated by the probes derived from the mRNAs from the PBMC stimulated with LPS is more than twice stronger than that from the PBMC not stimulated with LPS at all of the spots.
  • cDNA tags By using the cDNA tags optionally selected from the library of the cDNA tags obtained in example 1, gene expression differences between a pair of samples can be analyzed.
  • cDNAs prepared with a reverse transcriptase by using, mRNAs derived from peripheral blood mononuclear cells (PBMC) stimulated with LPS and mRNAs derived from PBMC not stimulated with LPS as a template, are spotted on a nylon membrane and then the cDNAs on the membrane are incubated at 80 degrees Celsius for two hours.
  • PBMC peripheral blood mononuclear cells
  • An oligo DNA comprising the sequence of mfID65462282 selected from the genes whose expression are induced by LPS stimulation as shown in Table 1 is synthesized and then labeled with [ gamma- P ] ATP (Amersham Pharmacia) by T4 polynucleotide kinase to obtain a probe solution including the probe labeled with 32 P (radioisotope).
  • This probe solution is used to perform a hybridization with said nylon membrane in 6 x SET overnight at 45 degrees Celsius. After the nylon membrane is washed with washing solution [6 x SSC, 0.1 % SDS] at 52 degrees Celsius, and then performed autoradiography.
  • the signals on X-ray film of the cDNA derived from the mRNA of LPS stimulated PBMC is twice stronger than those of LPS non-stimulated PBMC.
  • a library of cDNA tags for identifying expressed genes was prepared in the same manner used in example 1 except that Afal was used instead of Csp6I as a type
  • Base "A” was ligated to the blunt end of the cDNA in the sample formed by cleaving with type II restriction enzyme Afal in the presence of dATP in the following manner. 5' - AC • • • • • - 3 3' - ATG • • • • - 5'
  • linker X having the following structure.
  • Base "T” was deleted from the blunt end of the cDNA in the sample formed by cleaving with type II restriction enzyme Afal in the presence of dGTP in the following manner.
  • linker X-cDNA fragments were cleaved with Bsgl by utilizing the recognition site of restriction enzyme Bsgl "5'-GTGCAG-3' " in the linker X.
  • the mixture of cleaved products were centrifuged and the supernatant was collected. Since the cleavage site of the enzyme is at positon 5'-GTGCAG-3'(16/14), the collected fragments includes tags of 13 base pairs derived from the cDNA following the linker X.
  • linker Ys having the structure illustrated below were ligated.
  • a desired library of the cDNA tags were obtained by treating in the same manner as described in example 1 and digesting with the first and third type IIS restriction enzymes.
  • the gene expression may be analyzed by detecting the library of the cDNA tags obtained in example 4 with a detector described below.
  • a DNA chip is produced by synthesizing oligo DNAs corresponding to mf IDs 65462282, 55149444, 17350558, 58058765, 27500370 and 49078651 of the genes listed in Table 1 whose expression is activated by LPS stimulation, and spotting on a slide glass with the oligo DNAs using a conventional method.
  • a probe solution is prepared by labeling mRNAs derived from peripheral blood mononuclear cells (PBMC) obtained by LPS stimulation in example 1 which are used as a template with a fluorescent marker, fluorescent compound Cy3-dUTP
  • PBMC not stimulated with LPS which are used as a template with a fluorescent marker, fluorescent compound Cy5-dUTP (Amersham Pharmacia)(*2: see example 2).
  • the probe solutions are mixed together to make 6 X SET [0.9M NaCl, 10 ⁇ g/ml Yeast tRNA, 0.1 %SDS, 120mM Tris-HCl(pH7.8)] solution and then kept in contact with said oligo DNA chip at 45 degrees Celsius overnight to perform hybridization.
  • the fluorescent markers on the chip are scanned with a scanner to obtain the fluorescence intensity data and then the data was analyzed.
  • the scatter plot of signal intensity of Cy3 and Cy5 at each of the spots demonstrates that the fluorescent light radiated by the probes derived from the mRNAs from the PBMC stimulated with LPS is more than twice stronger than that from the PBMC not stimulated with LPS at all of the spots.
  • cDNAs to be tested or genes specifically expressed in cells to be tested can be accurately detected with a high reproducibility to analyze.
  • a method of the present invention can indicate differences of gene expression between optional two kinds of cells to clarify differences in their functions and morphologies. The method is therefore applicable to analysis of huge aspect of biological phenomena under a physiological condition or a diseased state.
  • the present inventors developed a method for the preparation of cDNA tags for identifying expressed genes and a method for the analysis of gene expression, and applied as PCT application No. PCT/JP02/02338 for the invention before filing this application.
  • the present invention provides the method for the preparation of the cDNA tags and the method for the analysis of gene expression which are improved in that a wider selection of the restriction enzymes used may be allowed than those of the prior invention and the preparation of the linkers used may be prepared easier than those used in the prior invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé pour préparer des marqueurs d'ADNc servant à d'identifier des gènes exprimés et un procédé d'analyse d'expression génétique. Les marqueurs d'ADNc servant à identifier des gènes exprimés sont préparés selon ledit procédé consistant à combiner une enzyme de restriction de type II et trois sortes d'enzymes de restriction de type IIS, et une séquence de liaison X présentant des sites de reconnaissance pour la première et la deuxième enzyme de restriction de type IIS et une séquence de liaison Y présentant un site de reconnaissance pour la troisième enzyme de restriction de type IIS. Lesdits marqueurs d'ADNc peuvent être utilisés seuls ou en combinaison, par exemple sous forme de chaîne (concatémère) obtenue selon un procédé combinatoire, pour analyser de manière efficace l'expression génétique.
PCT/JP2003/009901 2002-09-12 2003-08-05 Procede pour preparer des marqueurs d'adnc servant a identifier des genes exprimes et procede d'analyse d'expression genetique WO2004024953A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003250546A AU2003250546A1 (en) 2002-09-12 2003-08-05 Method for preparation of cdna tags for identifying expressed genes and method for analysis of gene expression
EP03795210A EP1537242A1 (fr) 2002-09-12 2003-08-05 Procede pour preparer des marqueurs d'adnc servant a identifier des genes exprimes et procede d'analyse d'expression genetique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002-267163 2002-09-12
JP2002267163A JP2004097158A (ja) 2002-09-12 2002-09-12 発現遺伝子同定用ｃＤＮＡタグの作成方法、及び該ｃＤＮＡタグを用いる遺伝子発現解析方法

Publications (1)

Publication Number Publication Date
WO2004024953A1 true WO2004024953A1 (fr) 2004-03-25

Family

ID=31986689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/009901 WO2004024953A1 (fr) 2002-09-12 2003-08-05 Procede pour preparer des marqueurs d'adnc servant a identifier des genes exprimes et procede d'analyse d'expression genetique

Country Status (5)

Country Link
EP (1) EP1537242A1 (fr)
JP (1) JP2004097158A (fr)
AU (1) AU2003250546A1 (fr)
TW (1) TW200404891A (fr)
WO (1) WO2004024953A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008095927A1 (fr) * 2007-02-05 2008-08-14 Philipps-Universität Marburg Procédé permettant de cloner au moins une molécule d'acide nucléique d'intérêt au moyen d'endonucléases de restriction de type iis, et vecteurs de clonage, trousses et système correspondants faisant appel à ces endonucléases de restriction de type iis
EP2032721A1 (fr) * 2006-06-09 2009-03-11 Agency for Science, Technology and Research Concatenation d'acide nucleique
WO2014144713A3 (fr) * 2013-03-15 2014-11-27 Lineage Biosciences, Inc. Méthode de séquençage du répertoire immunitaire
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202004286UA (en) * 2014-05-08 2020-06-29 Fluidigm Corp Integrated single cell sequencing

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0761822A2 (fr) * 1995-09-12 1997-03-12 The Johns Hopkins University School Of Medicine Méthode d'analyse sérielle de l'expression de gènes
US5710000A (en) * 1994-09-16 1998-01-20 Affymetrix, Inc. Capturing sequences adjacent to Type-IIs restriction sites for genomic library mapping
WO1998014619A1 (fr) * 1996-10-03 1998-04-09 Incyte Pharmaceuticals, Inc. Procedes de generation et d'analyse de marqueurs de transcrits
US5981190A (en) * 1997-01-08 1999-11-09 Ontogeny, Inc. Analysis of gene expression, methods and reagents therefor
DE19945765A1 (de) * 1999-03-22 2000-10-05 Paul Cullen Nukleinsäurekombination
US6136537A (en) * 1998-02-23 2000-10-24 Macevicz; Stephen C. Gene expression analysis
EP1156107A1 (fr) * 1999-02-17 2001-11-21 Ajinomoto Co., Inc. Procede d'analyse d'une frequence d'expression genique
WO2002074951A1 (fr) * 2001-03-15 2002-09-26 Kureha Chemical Industry Company, Limited Procede de construction d'un marqueur d'adnc servant a identifier un gene exprime, et procede d'analyse de l'expression d'un gene

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710000A (en) * 1994-09-16 1998-01-20 Affymetrix, Inc. Capturing sequences adjacent to Type-IIs restriction sites for genomic library mapping
EP0761822A2 (fr) * 1995-09-12 1997-03-12 The Johns Hopkins University School Of Medicine Méthode d'analyse sérielle de l'expression de gènes
WO1998014619A1 (fr) * 1996-10-03 1998-04-09 Incyte Pharmaceuticals, Inc. Procedes de generation et d'analyse de marqueurs de transcrits
US5981190A (en) * 1997-01-08 1999-11-09 Ontogeny, Inc. Analysis of gene expression, methods and reagents therefor
US6136537A (en) * 1998-02-23 2000-10-24 Macevicz; Stephen C. Gene expression analysis
EP1156107A1 (fr) * 1999-02-17 2001-11-21 Ajinomoto Co., Inc. Procede d'analyse d'une frequence d'expression genique
DE19945765A1 (de) * 1999-03-22 2000-10-05 Paul Cullen Nukleinsäurekombination
WO2002074951A1 (fr) * 2001-03-15 2002-09-26 Kureha Chemical Industry Company, Limited Procede de construction d'un marqueur d'adnc servant a identifier un gene exprime, et procede d'analyse de l'expression d'un gene

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
LAKEN S J ET AL: "Genotyping by mass spectrometric analysis of short DNA fragments", NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 16, pages 1352 - 1356, XP002138136, ISSN: 1087-0156 *
POWELL J: "Enhanced concatemer cloning-a modification to the SAGE (Serial Analysis of Gene Expression) technique.", NUCLEIC ACIDS RESEARCH. ENGLAND 15 JUL 1998, vol. 26, no. 14, 15 July 1998 (1998-07-15), pages 3445 - 3446, XP002260216, ISSN: 0305-1048 *
RYO A ET AL: "A modified serial analysis of gene expression that generates longer sequence tags by nonpalindromic cohesive linker ligation.", ANALYTICAL BIOCHEMISTRY. UNITED STATES 1 JAN 2000, vol. 277, no. 1, 1 January 2000 (2000-01-01), pages 160 - 162, XP002260215, ISSN: 0003-2697 *
RYO A ET AL: "Serial analysis of gene expression in HIV-1-infected T cell lines", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 462, no. 1-2, 26 November 1999 (1999-11-26), pages 182 - 186, XP004260612, ISSN: 0014-5793 *
See also references of EP1537242A1 *
YAMAMOTO M ET AL: "Use of serial analysis of gene expression (SAGE) technology", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 250, no. 1-2, 1 April 2001 (2001-04-01), pages 45 - 66, XP004230694, ISSN: 0022-1759 *
YAMAMOTO MIKIO: "[Gene expression profiling using improved SAGE]", RINSHO BYORI. THE JAPANESE JOURNAL OF CLINICAL PATHOLOGY. JAPAN JAN 2002, vol. 50, no. 1, January 2002 (2002-01-01), pages 52 - 60, XP008023957, ISSN: 0047-1860 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2032721A1 (fr) * 2006-06-09 2009-03-11 Agency for Science, Technology and Research Concatenation d'acide nucleique
EP2032721A4 (fr) * 2006-06-09 2010-06-02 Agency Science Tech & Res Concatenation d'acide nucleique
WO2008095927A1 (fr) * 2007-02-05 2008-08-14 Philipps-Universität Marburg Procédé permettant de cloner au moins une molécule d'acide nucléique d'intérêt au moyen d'endonucléases de restriction de type iis, et vecteurs de clonage, trousses et système correspondants faisant appel à ces endonucléases de restriction de type iis
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
WO2014144713A3 (fr) * 2013-03-15 2014-11-27 Lineage Biosciences, Inc. Méthode de séquençage du répertoire immunitaire
EP3327123A1 (fr) * 2013-03-15 2018-05-30 Lineage Biosciences, Inc. Méthode de séquençage du répertoire immunitaire
EP3611262A1 (fr) * 2013-03-15 2020-02-19 Lineage Biosciences, Inc. Méthode de séquençage du répertoire immunitaire
US10722858B2 (en) 2013-03-15 2020-07-28 Lineage Biosciences, Inc. Methods and compositions for tagging and analyzing samples
US11161087B2 (en) 2013-03-15 2021-11-02 Lineage Biosciences, Inc. Methods and compositions for tagging and analyzing samples

Also Published As

Publication number Publication date
EP1537242A1 (fr) 2005-06-08
AU2003250546A1 (en) 2004-04-30
TW200404891A (en) 2004-04-01
JP2004097158A (ja) 2004-04-02

Similar Documents

Publication Publication Date Title
EP3541956B1 (fr) Procédé de marquage spatial et d'analyse d'acides nucléiques dans un échantillon biologique
EP0994969B1 (fr) Categorisation de l'acide nucleique
EP3511423B1 (fr) Procédés et produits pour optimiser la détection localisée ou spatiale de l'expression génique dans un échantillon de tissu
US5712126A (en) Analysis of gene expression by display of 3-end restriction fragments of CDNA
Pastorian et al. Optimization of cDNA representational difference analysis for the identification of differentially expressed mRNAs
AU753505B2 (en) Probe arrays and methods of using probe arrays for distinguishing DNA
US20030175908A1 (en) Methods and means for manipulating nucleic acid
US5827658A (en) Isolation of amplified genes via cDNA subtractive hybridization
NZ334426A (en) Characterising cDNA comprising cutting sample cDNAs with a first endonuclease, sorting fragments according to the un-paired ends of the DNA, cutting with a second endonuclease then sorting the fragments
JP2004535162A (ja) Ｒｎａ配列の増幅のための方法および組成物
MXPA03000575A (es) Metodos para analisis e identificacion de genes transcritos e impresion dactilar.
WO1997007244A1 (fr) SEPARATION DE GENES AMPLIFIES, PAR HYBRIDATION SOUSTRACTIVE D'ADNc
US6183995B1 (en) Methods of measuring gene expression using wax-embedded tissue specimens
EP1369477A1 (fr) Procede de construction d'un marqueur d'adnc servant a identifier un gene exprime, et procede d'analyse de l'expression d'un gene
US6232065B1 (en) Analysis of gene family expression
EP1537242A1 (fr) Procede pour preparer des marqueurs d'adnc servant a identifier des genes exprimes et procede d'analyse d'expression genetique
US20060240431A1 (en) Oligonucletide guided analysis of gene expression
WO2000018966A2 (fr) Nouvelle strategie d'analyse genetique a l'echelle du genome: procedures integrees d'identification genique
WO2003064689A2 (fr) Procedes et dispositifs pour l'identification de caracteristiques geniques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003795210

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003795210

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003795210

Country of ref document: EP